当前位置：
X-MOL 学术
›
Lancet Oncol.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis
The Lancet Oncology ( IF 41.6 ) Pub Date : 2024-10-19 , DOI: 10.1016/s1470-2045(24)00457-1 Antonio D'Alessio MD, Bernardo Stefanini MD, Julia Blanter MD, Benjamin Adegbite MD, Fionnuala Crowley MD, Vincent Yip MD, Sarah Slater MD, Claudia Angela Maria Fulgenzi MD, Ciro Celsa MD PhD, Giulia Francesca Manfredi MD, Madhava Pai MD, Prof Robert D Goldin MD, Stephen C Ward MD PhD, Maria Isabel Fiel MD, Daniel H Shu MD, Yung-Yeh Su MD PhD, Alessio Cortellini MD PhD, Marina Baretti MD, Robert Anders MD, Mark Yarchoan MD, Prof Chiun Hsu MD PhD, Thomas U Marron MD PhD, David J Pinato MD PhD
The Lancet Oncology ( IF 41.6 ) Pub Date : 2024-10-19 , DOI: 10.1016/s1470-2045(24)00457-1 Antonio D'Alessio MD, Bernardo Stefanini MD, Julia Blanter MD, Benjamin Adegbite MD, Fionnuala Crowley MD, Vincent Yip MD, Sarah Slater MD, Claudia Angela Maria Fulgenzi MD, Ciro Celsa MD PhD, Giulia Francesca Manfredi MD, Madhava Pai MD, Prof Robert D Goldin MD, Stephen C Ward MD PhD, Maria Isabel Fiel MD, Daniel H Shu MD, Yung-Yeh Su MD PhD, Alessio Cortellini MD PhD, Marina Baretti MD, Robert Anders MD, Mark Yarchoan MD, Prof Chiun Hsu MD PhD, Thomas U Marron MD PhD, David J Pinato MD PhD
Neoadjuvant use of immune checkpoint inhibitors (ICIs) before liver resection results in pathological tumour regression in patients with hepatocellular carcinoma. We aimed to describe the characteristics of pathological responses after preoperative ICI therapy for hepatocellular carcinoma and to evaluate the association between the depth of tumour regression and relapse-free survival.
中文翻译：
肝细胞癌患者新辅助免疫检查点抑制剂后的病理反应：一项跨试验、患者水平的分析
肝切除术前新辅助使用免疫检查点抑制剂 （ICI） 可导致肝细胞癌患者的病理肿瘤消退。我们旨在描述肝细胞癌术前 ICI 治疗后病理反应的特征，并评估肿瘤消退深度与无复发生存期之间的关联。
更新日期：2024-10-19
中文翻译：
肝细胞癌患者新辅助免疫检查点抑制剂后的病理反应：一项跨试验、患者水平的分析
肝切除术前新辅助使用免疫检查点抑制剂 （ICI） 可导致肝细胞癌患者的病理肿瘤消退。我们旨在描述肝细胞癌术前 ICI 治疗后病理反应的特征，并评估肿瘤消退深度与无复发生存期之间的关联。
京公网安备 11010802027423号